title: Modulation of adipokines and vascular remodelling markers during OGTT with acarbose or pioglitazone treatment.
abstract: Adipose tissue secretes biologically active mediators as adipokines. We evaluate the effect of pioglitazone and acarbose on adipokines and vascular remodelling markers during an oral glucose tolerance test (OGTT). Height and body weight, BMI, glycemic and lipid profile, blood pressure, Nitrites/nitrates, ADP, resistin, MMP-2, and MMP-9 were evaluated at titration beginning, after 3, 6 months, and at the study end in 473 type 2 diabetic patients. BMI and weight increased after full treatment with pioglitazone respect to acarbose. HbA(1c) decreased after titration period with pioglitazone compared to baseline and to acarbose, and after full treatment with pioglitazone compared to the end of titration period and to acarbose. FPG decreased after full treatment with pioglitazone compared to the end of titration period. PPG decreased with acarbose after titration period respect to baseline and after full treatment respect to the end of titration period. FPI and Homa index decreased after titration period with pioglitazone compared to baseline and to acarbose, and after full treatment with pioglitazone respect to the end of titration period and to acarbose. ADP increased after titration period with pioglitazone compared to baseline and to acarbose, and after full treatment with pioglitazone compared to the end of titration period and to acarbose. Resistin decreased after titration period with pioglitazone compared to baseline and to acarbose, and after full treatment with pioglitazone respect to acarbose. Pioglitazone improves glucose metabolism and insulin-resistance compared to acarbose in type 2 diabetic patients already treated with metformin and sulphonilureas.
authors.affiliation: Department of Internal Medicine and Therapeutics, University of Pavia, Fondazione IRCCS Policlinico S. Matteo, P.le C. Golgi 2, 27100 PAVIA, Italy. giuseppe.derosa@unipv.it
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Derosa
authors.forename: Angela
authors.initials: A
authors.lastname: D'Angelo
authors.forename: Sibilla A T
authors.initials: SA
authors.lastname: Salvadeo
authors.forename: Ilaria
authors.initials: I
authors.lastname: Ferrari
authors.forename: Elena
authors.initials: E
authors.lastname: Fogari
authors.forename: Alessia
authors.initials: A
authors.lastname: Gravina
authors.forename: Roberto
authors.initials: R
authors.lastname: Mereu
authors.forename: Ilaria
authors.initials: I
authors.lastname: Palumbo
authors.forename: Pamela
authors.initials: P
authors.lastname: Maffioli
authors.forename: Sabrina
authors.initials: S
authors.lastname: Randazzo
authors.forename: Arrigo F G
authors.initials: AF
authors.lastname: Cicero
mesh_terms: D020909:Acarbose / Q000494:pharmacology*; D054392:Adipokines / Q000378:metabolism; D015415:Biomarkers / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D005947:Glucose / Q000378:metabolism; D005951:Glucose Tolerance Test; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D007333:Insulin Resistance; D008297:Male; D008875:Middle Aged; D000077205:Pioglitazone; D045162:Thiazolidinediones / Q000494:pharmacology*
chemical_list: D020909:Acarbose; D054392:Adipokines; D015415:Biomarkers; D005947:Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D000077205:Pioglitazone; D045162:Thiazolidinediones